Literature DB >> 8478239

Malignant glioma--timing of response to radiation therapy.

L E Gaspar1, B J Fisher, D R MacDonald, D V LeBer, E C Halperin, S C Schold, J G Cairncross.   

Abstract

PURPOSE: The response of malignant gliomas to radiation was examined retrospectively in 71 patients with newly diagnosed supratentorial malignant gliomas. Questions asked included frequency, timing and clinical significance of response. METHODS AND MATERIALS: After surgery, all were treated with whole brain plus boost radiotherapy followed 8 weeks later by chemotherapy. The rate, degree, and timing of response to radiation were determined by comparing postoperative, end of radiation, and prechemotherapy CT scans on each patient.
RESULTS: Postoperative residual tumor was evident on 63/71 postoperative scans. Twenty-two of 63 tumors (35%) had a partial or complete response to radiation. Twenty (32%) had responded by the end of radiation; 17 maximally. Six to 8 weeks later, three responding tumors had responded further and two previously stable ones had begun to respond. Only three tumors (5%) responded completely. A greater proportion of anaplastic gliomas than glioblastomas responded to radiation (52% vs. 26%). Protracted or delayed responses were only observed in patients with anaplastic glioma. Patients who responded to radiation did not live significantly longer than non-responders. However, tumor progression prior to chemotherapy was associated with significantly shorter survival.
CONCLUSION: This CT scan-based analysis demonstrates that malignant gliomas are only moderately radioresponsive tumors and also demonstrates that response to radiation, if it is going to occur, is usually evident by the end of treatment.

Entities:  

Mesh:

Year:  1993        PMID: 8478239     DOI: 10.1016/0360-3016(93)90318-p

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  Short-course radiotherapy in elderly and frail patients with glioblastoma multiforme. A phase II study.

Authors:  B Jeremic; Y Shibamoto; D Grujicic; B Milicic; M Stojanovic; N Nikolic; A Dagovic; J Aleksandrovic
Journal:  J Neurooncol       Date:  1999-08       Impact factor: 4.130

2.  Radiotherapy after hyperbaric oxygenation for malignant gliomas: a pilot study.

Authors:  K Kohshi; Y Kinoshita; H Terashima; N Konda; A Yokota; T Soejima
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

3.  Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM).

Authors:  Carmen Balaña; Antonio López-Pousa; Alfonso Berrocal; Ricardo Yaya-Tur; Ana Herrero; Jose-Luis García; Javier Martín-Broto; Manuel Benavides; Miguel Cerdá-Nicolás; Rosa Ballester; Josep Balart; Jaume Capellades
Journal:  J Neurooncol       Date:  2004-12       Impact factor: 4.130

4.  Metastatic seeding of the stereotactic biopsy tract in glioblastoma multiforme: case report and review of the literature.

Authors:  M P Steinmetz; G H Barnett; B S Kim; M A Chidel; J H Suh
Journal:  J Neurooncol       Date:  2001-12       Impact factor: 4.130

5.  Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma.

Authors:  Daniel A Hamstra; Thomas L Chenevert; Bradford A Moffat; Timothy D Johnson; Charles R Meyer; Suresh K Mukherji; Douglas J Quint; Stephen S Gebarski; Xiaoying Fan; Christina I Tsien; Theodore S Lawrence; Larry Junck; Alnawaz Rehemtulla; Brian D Ross
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-02       Impact factor: 11.205

6.  Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival.

Authors:  Daniel A Hamstra; Craig J Galbán; Charles R Meyer; Timothy D Johnson; Pia C Sundgren; Christina Tsien; Theodore S Lawrence; Larry Junck; David J Ross; Alnawaz Rehemtulla; Brian D Ross; Thomas L Chenevert
Journal:  J Clin Oncol       Date:  2008-06-09       Impact factor: 44.544

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.